Guggenheim Downgrades Revance Therapeutics to Neutral
Portfolio Pulse from Benzinga Newsdesk
Guggenheim analyst Seamus Fernandez has downgraded Revance Therapeutics (NASDAQ:RVNC) from Buy to Neutral.
August 12, 2024 | 7:21 pm
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
Guggenheim analyst Seamus Fernandez downgraded Revance Therapeutics from Buy to Neutral, indicating a less optimistic outlook on the stock.
The downgrade from Buy to Neutral by a reputable analyst suggests a less favorable view on the stock's short-term performance, likely leading to a negative impact on the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100